![Dhavalkumar Patel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : 328 383 $ au 31/05/2026
Dhavalkumar Patel a fondé Priothera Ltd. Actuellement, le Dr Patel est Chief Scientific Officer & Executive VP chez UCB SA. Il est également membre du conseil d'administration de 6 autres sociétés. Au cours de sa carrière, le Dr Patel a occupé les postes de directeur de la recherche aux Instituts Novartis pour la recherche biomédicale, Inc. et de directeur mondial de l'immunité chez Novartis International AG, de professeur à l'Université de Caroline du Nord à Chapel Hill et de professeur au Duke University Medical Center. Dhavalkumar Patel a obtenu un doctorat, un diplôme de premier cycle et un diplôme d'études supérieures à l'université Duke.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SANA BIOTECHNOLOGY, INC. 0,04 % | 24/03/2026 | 99 510 ( 0,04 % ) | 328 383 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 02/04/2020 |
| SANA BIOTECHNOLOGY, INC. | Directeur Technique/Scientifique/R&D | 26/08/2024 |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Directeur/Membre du Conseil | - |
Anokion SA
 Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Directeur/Membre du Conseil | - |
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops and supplies immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases | Directeur/Membre du Conseil | - |
Mimetas BV
 Mimetas BV BiotechnologyHealth Technology Develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models | Président | 01/09/2022 |
| Sociétés | Poste | Fin |
|---|---|---|
| UCB | Directeur Technique/Scientifique/R&D | 01/07/2024 |
Inflazome Ltd.
 Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutic medicines for inflammatory diseases | Directeur/Membre du Conseil | 01/09/2020 |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Offers healthcare solutions | Corporate Officer/Principal | 01/01/2017 |
| ░░░ ░░░░░░░░░░ ░░ ░░░░░ ░░░░░░░░ ░░ ░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 15 |
|---|---|
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Offers healthcare solutions | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UCB SA
 UCB SA Pharmaceuticals: MajorHealth Technology Manufactures biopharmaceutical products | Health Technology |
The University of North Carolina at Chapel Hill
 The University of North Carolina at Chapel Hill Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Duke University Medical Center
 Duke University Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Duke University School of Medicine
 Duke University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Anokion SA
Anokion SA BiotechnologyHealth Technology Operates as a biotechnology company which develops therapies for antigen-specific immune tolerance | Health Technology |
Mimetas BV
Mimetas BV BiotechnologyHealth Technology Develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models | Health Technology |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies for type 1 diabetes | Health Technology |
Inflazome Ltd.
Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Develops therapeutic medicines for inflammatory diseases | Health Technology |
Sana Biotechnology, Inc.
 Sana Biotechnology, Inc. BiotechnologyHealth Technology Operates as a biotechnological company which creates and delivers engineered cells as medicine for patients | Health Technology |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops and supplies immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases | Health Technology |
Priothera Ltd.
 Priothera Ltd. Pharmaceuticals: MajorHealth Technology Develops hematological malignancies cells | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
